nextgener
sequenc
ng
highthroughput
massiv
parallel
sequenc
technolog
use
variou
applic
includ
wholegenom
sequenc
exom
sequenc
rna
sequenc
abstract
emerg
rna
sequenc
rnaseq
technolog
rnabas
biomolecul
hold
expand
promis
diagnost
prognost
therapeut
applic
variou
diseas
includ
cancer
infecti
diseas
detect
gene
fusion
differenti
express
known
diseasecaus
transcript
rnaseq
repres
immedi
opportun
howev
divers
rna
speci
detect
rnaseq
hold
new
promis
multifacet
clinic
applic
rnabas
measur
includ
potenti
extracellular
rna
noninvas
diagnost
indic
diseas
ongo
effort
toward
establish
benchmark
standard
assay
optim
clinic
condit
demonstr
assay
reproduc
requir
expand
clinic
util
rnaseq
c
l
l
n
p
u
b
l
h
e
r
l
e
l
l
r
g
h
r
e
e
r
v
e
technolog
platform
depend
genom
annot
predesign
speciesspecif
transcriptspecif
probe
transcript
measur
rnaseq
technolog
function
open
platform
allow
unbias
detect
known
novel
transcript
rna
dynam
divers
biomolecul
essenti
role
numer
biolog
process
molecular
diagnost
standpoint
rnabas
measur
potenti
broad
applic
across
divers
area
human
health
includ
diseas
diagnosi
prognosi
therapeut
select
technolog
advanc
continu
shape
way
rnabas
measur
use
clinic
box
evolut
nextgener
sequenc
ng
technolog
use
rna
sequenc
rnaseq
investig
vast
divers
rna
speci
obviou
excit
applic
open
entir
new
opportun
improv
diagnosi
treatment
human
diseas
rnaseq
provid
indepth
view
transcriptom
detect
novel
rna
transcript
variat
beyond
oper
open
platform
technolog
rnaseq
number
potenti
advantag
gene
express
microarray
includ
increas
dynam
rang
express
measur
focal
chang
singl
nucleotid
variant
snv
insert
delet
detect
differ
transcript
isoform
splice
variant
chimer
gene
fusion
includ
previous
unidentifi
gene
andor
transcript
fundament
perform
speci
although
rnaseq
assay
commerci
avail
earli
test
beli
consider
promis
broader
applic
rnaseqbas
clinic
test
review
select
current
potenti
clinic
applic
rnaseq
focus
differenti
express
rare
fusion
transcript
detect
allelespecif
express
discuss
emerg
area
pathogen
detect
measur
noncod
rna
ncrna
speci
overview
clinic
relev
rna
speci
discuss
within
review
summar
within
fig
focus
rna
speci
hold
greatest
promis
directli
impact
current
futur
clinic
test
understand
full
divers
rna
speci
put
role
cover
review
addit
review
ng
assay
technolog
topic
well
review
beyond
intend
scope
finish
discuss
challeng
face
translat
technolog
clinic
practic
includ
regulatori
environ
ongo
effort
establish
refer
standard
best
practic
rnaseq
clinic
test
capabl
high
reproduc
accuraci
precis
opportun
enabl
rnaseq
wholegenom
wholeexom
sequenc
rnaseq
involv
sequenc
sampl
billion
base
across
ten
hundr
million
pair
unpair
shortread
vast
amount
shortread
rnaseq
data
must
bioinformat
realign
assembl
detect
measur
express
hundr
thousand
rna
transcript
rnaseq
detect
underli
genom
alter
singl
nucleotid
resolut
within
express
region
genom
also
quantifi
express
level
captur
variat
detect
genom
level
includ
singl
nucleotid
variant
snv
singl
nucleotid
g
c
alter
dna
sequenc
express
altern
transcript
similar
serial
analysi
gene
express
sage
predecessor
tagbas
sequenc
method
genomewid
express
analysi
rnaseq
allow
quantif
transcript
without
predefin
rna
target
interest
provid
improv
detect
rna
splice
event
unlik
histor
platform
clinic
rna
measur
microarray
quantit
revers
transcript
pcr
qrtpcr
rnaseq
fundament
open
platform
technolog
allow
quantif
known
predefin
rna
speci
capabl
detect
quantifi
rare
novel
rna
transcript
variant
within
sampl
rnaseq
also
greater
dynam
rang
quantifi
transcript
express
compar
microarray
technolog
provid
potenti
increas
detect
vari
ation
within
sampl
overal
rnaseq
identifi
thousand
differenti
express
gene
ten
thousand
differenti
express
gene
isoform
detect
mutat
germlin
variat
hundr
thousand
express
genet
variant
thu
facilit
assess
allelespecif
express
variant
well
detect
chimer
gene
fusion
transcript
isoform
splice
variant
addit
rnaseq
character
previous
unidentifi
transcript
divers
type
ncrna
includ
microrna
mi
rna
piwiinteract
rna
pirna
trna
inde
open
platform
rnaseq
detect
measur
tempor
dynam
rna
speci
set
stage
consider
challeng
even
consider
opportun
associ
rnaseq
move
clinic
test
environ
detect
aberr
transcript
human
diseas
mrna
express
profil
multigen
mrna
signaturebas
assay
increasingli
incorpor
clinic
manag
assay
use
variou
technolog
platform
measur
mrna
express
differ
multigen
panel
broad
clinic
applic
tabl
exampl
breast
cancer
recent
clinic
guidelin
support
use
multigen
mrnabas
prognost
assay
assist
treatment
decis
conjunct
clinicopatholog
factor
inde
oncotypedx
express
assay
recent
valid
prospect
conduct
studi
breast
cancer
clinic
relev
breast
cancer
gene
express
signatur
compar
use
microarray
rnaseq
report
strong
correl
express
gene
oncotypedx
mammoprint
signatur
across
platform
spearman
correl
respect
work
systemat
evalu
rnaseqbas
microarraybas
classifi
found
rnaseq
outperform
array
character
transcriptom
cancer
perform
similarli
array
clinic
endpoint
predict
allomap
noninvas
gene
expressionbas
blood
test
use
manag
clinic
care
heart
transplant
recipi
provid
quantifi
score
risk
reject
base
measur
express
gene
subset
relat
immun
system
activ
signal
potenti
use
rnaseq
immunerel
diseas
expand
rapidli
abil
quickli
target
sequenc
repertoir
cell
b
cell
receptor
patient
begin
matur
use
techniqu
adapt
biotechnolog
immunoseq
strategi
allow
examin
immunerel
diseas
immunotherapi
respons
new
way
exemplifi
recent
report
rnaseq
exom
sequenc
use
togeth
evalu
mutat
load
express
neoantigen
immun
microenviron
express
predictor
respons
immun
checkpoint
inhibitor
therapi
melanoma
gene
fusion
oncogen
gene
fusion
well
recogn
pathogen
role
cancer
case
recurr
gene
fusion
correl
specif
tumour
subtyp
allow
gene
fusion
statu
use
histor
gene
express
analysi
within
clinic
primarili
focus
around
singl
gene
test
use
quantit
revers
transcript
pcr
qrtpcr
detect
influenza
viru
method
sever
advantag
includ
fast
accur
sensit
highthroughput
term
number
clinic
sampl
analys
costeffect
requir
low
sampl
input
reason
histor
natur
platform
qrtpcr
gener
deem
gold
standard
method
measur
transcript
level
particularli
clinic
space
howev
number
limit
includ
fact
although
high
sampl
throughput
technolog
rel
marker
measur
made
singl
assay
initi
studi
describ
rel
reproduc
hybridizationbas
method
assess
express
multipl
gene
target
use
array
probe
solid
surfac
becam
clear
microarray
technolog
revolut
would
lead
new
opportun
clinic
assay
develop
measur
sever
rna
target
one
time
gene
express
profil
becam
associ
potenti
diagnost
prognost
paramet
research
crucial
assess
clinic
valid
technolog
multigen
profil
test
gene
express
standpoint
mammaprint
agendia
provid
excel
exampl
microarraybas
clinic
test
simultan
measur
express
gene
breast
tumour
profil
help
predict
risk
recurr
although
power
microarraybas
assay
limit
environ
relat
laboratorytolaboratori
variat
sampl
prepar
affect
reproduc
moreov
applic
microarray
signaltonois
ratio
affect
limit
detect
interestingli
number
addit
cancer
multigen
profil
test
clinic
avail
oncotypedx
genom
health
breast
cancer
recurr
risk
prolari
myriad
prostat
cancer
aggress
test
base
qrtpcr
technolog
rather
microarray
larg
owe
belief
qrtpcr
reliabl
reproduc
sensit
accur
enter
era
nextgener
sequenc
ng
technolog
rna
sequenc
rnaseq
brought
bear
clinic
gene
test
rnaseqbas
test
provid
unpreced
flexibl
sensit
accuraci
gene
express
measur
moreov
divers
rna
speci
open
simultan
measur
rare
transcript
splice
variant
noncod
rna
speci
exampl
divers
reach
rna
speci
rnaseq
becom
increasingli
relev
particularli
cancer
addit
provid
direct
detect
rna
fuse
gene
rnaseq
detect
specif
oncogen
splice
variant
egfr
androgen
receptor
probabl
prognost
therapeut
relev
inde
wherea
microarray
qrtpcr
close
platform
clearli
defin
transcript
detect
measur
rnaseq
open
platform
natur
likewis
abil
identifi
novel
transcript
may
introduc
clinic
interpret
challeng
perhap
analog
variant
unknown
signific
terminolog
found
clinic
genom
dna
sequenc
still
perhap
often
appreci
establish
standard
method
assess
reproduc
accuraci
precis
varieti
clinic
relev
condit
need
facilit
adopt
rnaseq
test
clinic
laboratori
set
highli
character
standard
control
materi
use
ensur
accuraci
compar
assay
statist
measur
strength
associ
two
rankord
variabl
evalu
close
situat
mutat
determin
whether
resid
differ
allel
dna
probe
system
use
detect
rearrang
involv
specif
loci
probe
region
design
breakpoint
label
one
colour
probe
region
breakpoint
label
anoth
colour
overlap
signal
yellow
red
green
probe
indic
normal
pattern
wherea
distinct
signal
red
green
indic
presenc
rearrang
genom
variant
singlenucleotid
variant
involv
larg
region
dna
includ
insert
delet
invers
duplic
diagnost
purpos
accord
world
health
organ
classif
diagnosi
acut
myeloid
leukaemia
aml
made
regardless
blast
count
base
detect
recurr
genet
abnorm
transloc
fusion
involv
isoform
runtrel
transcript
factor
fusion
also
known
gene
fusion
also
associ
prognosi
suggest
biomark
screen
assess
cancer
risk
exemplifi
fusion
involv
transmembran
proteas
serin
gene
vet
avian
erythroblastosi
viru
oncogen
homologu
erg
prostat
cancer
sever
us
food
drug
administr
fda
approv
target
agent
clinic
biomark
amen
rnaseq
includ
agent
activ
known
oncogen
fusion
prototyp
exampl
mark
efficaci
kinas
inhibitor
exampl
imatinib
involv
breakpoint
cluster
region
bcr
tyrosineprotein
kinas
chronic
myeloid
leukaemia
cml
karyotyp
typic
use
diagnosi
cml
qrtpcr
measur
transcript
recommend
monitor
molecular
respons
kinas
inhibitor
treatment
continu
advanc
longread
rnaseq
technolog
promis
expand
util
fusion
transcript
measur
allow
detect
mutat
phase
measur
across
full
fusion
transcript
recent
singlemolecul
longread
rnaseq
appli
longitudin
sampl
patient
cml
poor
treatment
respons
result
provid
clonal
view
rang
resist
mutat
distinguish
compound
mutat
rna
molecul
independ
alter
present
differ
molecul
fusion
transcript
author
report
sensit
detect
result
identif
sever
mutat
escap
detect
routin
clinic
analysi
one
proofofconcept
case
detect
known
drugresist
mutat
longitudin
patient
sampl
four
month
earlier
detect
sanger
sequenc
asid
monitor
fusion
transcript
level
treatment
current
clinic
guidelin
rare
recommend
rnabas
detect
gene
fusion
fusion
involv
echinoderm
microtubul
associ
protein
like
anaplast
lymphoma
receptor
tyrosin
kinas
alk
origin
report
subset
nonsmallcel
lung
cancer
nsclc
alk
inhibitor
crizotinib
ceritinib
gain
fda
approv
alkrearrangementposit
nsclc
respect
typic
detect
fluoresc
situ
hybrid
fish
use
commerci
breakapart
probe
flank
highli
conserv
transloc
breakpoint
alk
genom
locu
emerg
use
immunohistochemistrybas
strategi
detect
overexpress
alk
protein
recent
clinic
guidelin
recommend
use
qrtpcrbase
alk
fusion
detect
treatment
select
lung
cancer
owe
challeng
rna
sampl
qualiti
routin
formalinfix
paraffinembed
ffpe
patholog
sampl
well
risk
fals
neg
result
limit
detect
fusion
involv
novel
alk
fusion
partner
recent
year
clinic
detect
gene
fusion
advanc
beyond
assay
detect
individu
fusion
event
introduct
rnaseq
assay
allow
comprehens
evalu
potenti
gene
fusion
exampl
foundationon
heme
assay
use
rnaseq
genom
sequenc
detect
common
gene
fusion
haematolog
cancer
sarcoma
report
emerg
clinic
respons
patient
receiv
treatment
basi
gene
fusion
detect
assay
rnaseq
promis
expand
repertoir
detect
gene
fusion
captur
subtl
intrachromosom
rearrang
also
allow
detect
fusion
product
uncharacter
fusion
partner
effort
underway
catalogu
gene
fusion
detect
across
variou
tumour
type
use
rnaseq
data
although
addit
studi
need
defin
clinic
valu
identifi
fusion
altern
transcript
altern
transcript
variant
aris
splice
alter
structur
variant
identifi
implic
rang
human
diseas
includ
development
disord
neurodegen
disord
cancer
also
grow
evid
presenc
altern
transcript
therapeut
implic
exampl
express
altern
splice
androgen
receptor
variant
detect
circul
tumour
cell
men
castrationresist
prostat
cancer
associ
reduc
respons
androgen
receptordirect
therapi
similarli
express
tumourspecif
epiderm
growth
factor
receptor
egfr
variant
iii
egfrviii
transcript
well
describ
glioblastoma
aris
infram
delet
encompass
exon
ref
clinic
trial
target
egfrviii
underway
case
mechan
contribut
gener
altern
transcript
may
miss
exom
sequenc
altern
breast
cancer
transcript
identifi
subset
patient
breast
cancer
famili
histori
breast
andor
ovarian
cancer
notabl
patient
previous
test
neg
pathogen
mutat
convent
genom
analysi
anticip
rnaseq
data
provid
complet
view
alter
splice
diseasespecif
transcript
grow
bodi
transcriptom
data
rich
resourc
discoveri
diseasespecif
isoform
transcript
potenti
diagnost
marker
therapeut
target
allelespecif
express
allelespecif
express
ase
aris
multipl
mechan
includ
genet
imprint
xchromosom
inactiv
allelespecif
transcript
case
ase
associ
predisposit
diseas
one
translationcoupl
rna
decay
mechan
wherebi
aberr
mrna
prematur
stop
codon
recogn
degrad
eqtl
genom
loci
regul
quantit
phenotyp
trait
gene
express
genet
marker
loci
associ
measur
chang
gene
express
rna
sequenc
read
split
exampl
accommod
exon
junction
exrna
rna
found
outsid
cell
protect
within
vesicl
associ
rnabind
protein
includ
exogen
sequenc
common
mechan
ase
genom
imprint
wherebi
one
allel
silenc
dna
methyl
histon
modif
leav
bias
express
transcrib
singl
nucleotid
polymorph
snp
parentoforigin
specif
manner
imprint
gene
cluster
frequent
associ
human
diseas
diseas
syndrom
aris
alter
singl
nonsilenc
parent
allel
exampl
angelman
syndrom
neurogenet
disord
associ
intellectu
disabl
speech
impair
risk
seizur
wellstudi
imprint
disord
caus
defici
matern
allel
express
ubiquitin
protein
ligas
brain
addit
epigenet
transcript
regul
posttranscript
mechan
altern
splice
proteintrunc
mutat
also
contribut
ase
exampl
variant
affect
splice
caus
exon
skip
lead
ase
variant
contain
within
exon
likewis
prematur
stop
codon
lead
nonsensemedi
decay
one
allel
result
ase
evalu
ase
within
rnaseq
data
inform
understand
regulatori
variat
aid
function
interpret
genet
variant
initi
applic
asernaseq
focus
genom
region
contribut
variat
transcript
express
level
term
express
quantit
trait
loci
look
nigerian
individu
intern
hapmap
project
rnaseq
lymphoblastoid
cell
line
deriv
individu
coupl
correspond
genotyp
hapmap
project
result
identif
gene
genet
variat
influenc
transcript
level
spli
cing
show
high
concord
polymorph
locat
near
gene
ase
recent
part
genotypetissu
express
gtex
program
rnaseq
carri
sampl
broad
rang
tissu
hundr
postmortem
donor
part
examin
influenc
genet
variat
gene
express
analys
ase
pilot
gtex
data
effect
truncat
mutat
nonsensemedi
transcript
decay
character
demonstr
util
use
rnaseq
ase
analysi
aid
function
interpret
genet
variant
dna
level
given
event
may
difficult
detect
predict
ase
import
correl
biomark
toward
identifi
pathogen
relev
genet
variant
overexpress
mutant
allel
may
indic
presenc
otherwis
unidentifi
promot
mutat
intron
variant
impact
splice
exampl
ase
analysi
transform
growth
factor
beta
receptor
observ
associ
increas
risk
colon
cancer
even
though
mechan
ase
identifi
within
work
use
rnaseq
ase
analysi
character
chromosom
parentoforigin
extent
xinactiv
femal
child
mild
cognit
impair
perform
familytrio
child
parent
wholeexom
sequenc
rnaseq
defin
de
novo
heterozyg
delet
encompass
kb
chromosom
x
contain
sever
gene
associ
neurolog
dysfunct
use
snp
phase
marker
demonstr
focal
delet
present
patern
allel
rnaseq
data
provid
abil
use
ase
analysi
estim
skew
xchromosom
inactiv
demonstr
favour
express
cytogenet
normal
matern
allel
suggest
contribut
observ
modest
phenotyp
notabl
rnaseq
provid
uniqu
advantag
tradit
humara
assay
measur
dna
methyl
androgen
receptor
gene
chromosom
x
provid
parentoforigin
chromosomewid
view
xinactiv
degner
et
al
provid
one
first
report
ascertain
rnaseq
readmap
allel
specif
demonstr
map
bia
allel
snp
repres
refer
sequenc
compar
altern
allel
thu
produc
referencebias
ase
filter
remov
bias
site
result
enrich
snp
ase
gene
previous
report
cisregulatori
mechan
gene
imprint
measur
ase
also
confound
difficulti
align
rna
split
read
harbour
neighbour
snp
small
indel
also
lead
referencebias
ase
recent
report
provid
recommend
bioinformat
analysi
data
process
address
challeng
introduc
tool
improv
detect
ase
rnaseq
data
extracellular
rna
investig
extracellular
rna
exrna
biofluid
monitor
diseas
rapidli
grow
area
diagnost
research
exrna
releas
cell
bodi
protect
degrad
carriag
within
extracellular
vesicl
associ
rnabind
protein
rbp
lipoprotein
measur
exrna
appeal
noninvas
method
monitor
diseas
biofluid
readili
access
tissu
frequent
longitudin
sampl
occur
transcript
mani
tissu
type
includ
neuron
brain
shown
access
detect
plasma
sampl
one
obviou
drawback
lack
tissu
specif
biofluid
contain
exrna
rbp
releas
mani
tissu
type
howev
size
organ
tissu
proxim
biofluid
influenc
rna
detect
exampl
plasma
sampl
high
level
transcript
releas
variou
rna
sequenc
rnaseq
methodolog
use
measur
divers
clinic
relev
rna
speci
small
rna
deep
sequenc
use
size
select
sequenc
variou
small
noncod
rna
includ
microrna
mi
rna
piwiinteract
rna
pirna
precursor
rna
measur
use
random
primer
amplif
oligo
dt
primer
use
select
polyadenyl
transcript
rnaseq
also
allow
detect
measur
altern
transcript
chimer
gene
fusion
transcript
viral
rna
transcript
well
evalu
allelespecif
express
hpv
human
papillomaviru
lncrna
long
noncod
rna
poli
polyadenyl
qrtpcr
quantit
revers
transcript
pcr
rrna
ribosom
rna
snorna
small
nucleolar
rna
vuss
variant
undetermin
signific
liver
heart
saliva
abund
transcript
salivari
gland
oesophagu
krvkj
unpublish
observ
recent
research
address
challeng
test
method
select
pull
extracellular
vesicl
deriv
specif
tissu
immunoprecipit
specif
membran
protein
cell
adhes
molecul
neuron
deriv
vesicl
use
exrna
cancer
detect
parallel
extra
cellu
lar
dna
mutat
detect
measur
rna
transcript
provid
mutat
transcrib
potenti
advantag
exrna
mani
copi
rna
dna
make
assess
potenti
sensit
differ
express
level
indic
organ
tissu
injur
diseas
way
describ
dna
measur
catalogu
exrna
contain
larg
number
mrna
rang
regulatori
rna
thoroughli
evalu
rnaseq
grow
interest
use
noninvas
analysi
exrna
monitor
diseas
use
chang
exrna
readout
key
diseas
pathway
indic
therapeut
efficaci
compani
exosom
diagnost
develop
exrnabas
clinic
laboratori
improv
amend
clia
diagnost
test
monitor
key
gene
fusion
mutat
egfr
plasma
sampl
exodx
lung
alk
first
test
measur
transcript
isol
exosom
plasma
patient
nsclc
notabl
sever
group
also
use
circul
rna
inform
provid
feedback
fetal
health
us
nation
center
advanc
translat
scienc
ncat
recent
launch
extracellular
rna
commun
consortium
develop
use
exrna
diagnost
tool
fund
sever
group
help
develop
catalogu
exrna
healthi
individu
number
diseas
increas
support
exrna
research
substanti
gain
understand
best
examin
biomolecul
overcom
variabl
detect
beyond
mrna
quantif
detect
altern
transcript
rnaseq
open
possibl
measur
consider
divers
rna
speci
includ
long
noncod
rna
lnc
rna
variou
short
rna
speci
includ
mi
rna
pirna
tabl
owe
stabil
regulatori
role
health
diseas
mi
rna
extens
examin
potenti
diagnost
marker
diseas
current
small
rnaseq
mi
rna
target
mirnaarray
platform
fallen
short
reliabl
crossplatform
accuraci
consider
obstacl
use
small
rnaseq
low
level
valid
observ
across
pcr
sequenc
platform
us
nation
institut
standard
technolog
nist
begun
develop
small
rna
control
extern
rna
control
support
valid
assay
result
improv
platform
necessari
next
step
util
small
rnaseq
discuss
later
section
small
regulatori
rna
mi
rna
best
studi
updat
wellcur
repositori
sequenc
inform
mirbas
increas
access
popular
small
rnaseq
grow
interest
use
technolog
categori
regulatori
rna
howev
correct
align
categor
hamper
state
small
rna
databas
small
rna
databas
wellmaintain
curat
genom
trna
databas
wherea
databas
maintain
sequenc
predict
experiment
valid
also
substanti
sequenc
overlap
categori
rna
pirna
trna
rrna
make
downstream
data
analysi
challeng
new
type
regulatori
rna
diagnost
potenti
unknown
circular
rna
circrna
recent
rediscov
rnaseq
experi
search
chromosom
rearrang
cancer
although
mani
group
identifi
new
circrna
potenti
function
role
total
genom
content
microbi
commun
member
complex
exampl
clinic
environment
sampl
human
microbiom
bodi
site
uniqu
microbiom
entireti
microbiom
individu
person
consid
person
panmicrobiom
cell
report
function
diseas
pathogenesi
howev
circrna
found
high
abund
biofluid
tissu
found
stabl
mrna
increas
potenti
diagnost
purpos
like
mani
target
translat
rnabas
sequenc
assay
near
futur
exampl
unbias
nontarget
metagenom
rnaseq
recent
use
directli
detect
influenza
viru
rna
respiratori
fluid
addit
viral
pathogen
detect
subset
case
public
health
context
rnaseq
use
track
origin
transmiss
pattern
ebola
viru
outbreak
west
africa
rnabas
amplicon
sequenc
also
explor
viral
quasispeci
mix
allel
popul
assess
hepat
c
viru
hcv
hiv
analys
necessari
clinic
determin
presenc
rel
quantiti
drugresist
mutat
patient
therapi
occur
minor
compon
larger
viral
popul
howev
clinic
applic
rnabas
diagnost
infecti
diseas
still
rare
beyond
qrtpcr
assay
viral
pathogen
microbi
exogen
small
rna
tremend
divers
exogen
rna
nonhuman
sourc
seen
human
plasma
indic
relationship
host
microbiom
food
sourc
andor
environ
sourc
import
microbi
exogen
rna
may
may
encapsul
outermembran
vesicl
still
explor
particularli
context
infect
howev
hold
great
deal
promis
new
diagnost
target
extens
analysi
pirna
implic
cancer
initi
studi
demonstr
associ
increas
express
pirna
poor
prognosi
softtissu
sarcoma
snrna
snrna
nucleotid
length
local
nucleu
function
rna
process
splice
circul
level
snrna
fragment
propos
potenti
diagnost
biomark
variou
tumour
type
includ
pancreat
cancer
colorect
cancer
snorna
snorna
two
main
class
box
cd
snorna
nucleotid
length
box
haca
snorna
nucleotid
snorna
play
key
role
ribosom
biogenesi
rrna
modif
level
snorna
andor
function
fragment
propos
potenti
clinic
diagnost
measur
applic
pursu
field
cancer
neurodegen
disord
two
snorna
recent
identifi
sputum
sampl
shown
potenti
use
diagnost
biomark
lung
cancer
lncrna
lncrna
repres
categori
ncrna
greater
nucleotid
length
function
regul
gene
express
lncrna
associ
cancer
prognosi
potenti
util
biomark
cancer
test
exointelliscor
prostat
includ
lncrna
biomark
circrna
circrna
lncrna
contain
coval
bond
end
result
continu
circular
loop
circrna
act
mirna
spong
regul
splice
transcript
although
littl
known
associ
circrna
diseas
initi
studi
explor
circrna
level
potenti
biomark
cancer
recent
studi
show
associ
reduc
level
specif
circrna
gastric
tumour
compar
adjac
nontumour
tissu
vitro
diagnost
test
provid
inform
critic
safe
effect
use
correspond
therapeut
agent
test
use
select
patient
treatment
specif
agent
includ
identifi
patient
popul
predict
efficaci
well
receiv
agent
due
low
likelihood
effect
possibl
seriou
advers
event
therapi
vitro
ex
vivo
vivo
catalogu
small
rna
produc
pathogen
way
sever
year
provid
comprehens
refer
databas
exogen
rna
signal
may
use
futur
clinic
infect
studi
exampl
ex
vivo
studi
neisseria
meningitidi
infect
human
blood
yield
dozen
small
rna
seem
associ
bacteraem
infect
similarli
multipl
studi
mycobacterium
tuberculosi
micrornaom
yield
numer
biomark
current
explor
diagnost
purpos
even
phenotypegenotyp
predict
diagnost
identifi
presenc
multidrug
resist
pathogen
mrna
measur
microbi
mrna
may
use
marker
infect
express
may
improv
detect
case
lowlevel
infect
exampl
bacteraemia
cerebrospin
fluid
infect
could
act
better
predictor
diseas
compar
direct
genom
detect
exampl
simpl
detect
human
papilloma
viru
hpv
dna
suffici
diagnos
hpvrelat
squamou
cell
carcinoma
hpv
dna
detect
healthi
control
women
thu
rnabas
diagnost
detect
hpv
develop
hpv
earli
onco
protein
mrna
detect
surrog
activ
infect
may
provid
better
predict
valu
cervic
cancer
host
rna
host
respons
form
mrna
signatur
also
like
becom
use
monitor
specif
infect
exampl
upregul
specif
host
immun
factor
interferon
beta
interferon
lambda
interferon
lambda
recent
demonstr
geno
type
hcv
infect
associ
acceler
liver
fibrosi
independ
risk
factor
hepatocellular
carcinoma
compar
nongenotyp
hcv
infect
host
micrornagen
interact
infect
respons
also
prove
fruit
sourc
potenti
diagnost
biomark
specif
infect
well
distinguish
activ
latent
infect
exampl
use
marker
discrimin
latent
infect
activ
diseas
tuberculosi
diagnost
use
small
rna
biomark
describ
review
number
hurdl
exist
develop
valid
infect
assay
includ
sensit
specif
perhap
difficult
overcom
normal
small
rna
clinic
sampl
vari
condit
tissu
individu
host
activ
area
studi
howev
applic
rnaseq
provid
use
orthogon
approach
genomicsbas
diagnost
clinic
microbiolog
challeng
move
rnaseq
clinic
translat
assay
clinic
translat
broader
adopt
laboratori
test
clinic
involv
evalu
demonstr
analyt
valid
clinic
valid
eventu
clinic
util
fig
analyt
valid
laboratori
test
must
deliv
accur
inform
reproduc
robust
perform
accuraci
determin
evalu
measur
calcul
valu
compar
refer
gold
standard
evalu
sensit
abil
detect
true
posit
specif
abil
detect
true
neg
test
must
also
provid
similar
result
repeat
test
reproduc
withstand
small
deliber
chang
preanalyt
analyt
variabl
associ
test
robust
establish
refer
standard
best
practic
measur
rnaseq
accuraci
reproduc
robust
initi
ad
hoc
individu
group
provid
initi
step
marioni
colleagu
provid
earliest
technic
assess
reproduc
measur
gene
express
level
rnaseq
report
high
reproduc
across
technic
replic
singl
rna
sampl
gene
denot
significantli
differenti
express
microarray
analysi
also
differenti
express
rnaseq
foldchang
correl
two
technolog
similar
better
report
comparison
differ
microarray
platform
rnaseq
detect
differenti
express
gene
microarray
ana
lysi
qrtpcr
confirm
subset
suggest
larg
proport
may
repres
true
posit
differ
may
result
broader
dynam
rang
rnaseq
andor
abil
resolv
splice
chang
genet
european
variat
diseas
geuvadi
consortium
demonstr
feasibl
reproduc
perform
rnaseq
across
multipl
laboratori
sequenc
lymphoblastoid
cell
line
individu
seven
sequenc
centr
use
singl
platform
basi
studi
consortium
propos
set
qualiti
check
assess
technic
bias
rnaseq
data
includ
differ
gc
content
fragment
size
transcript
length
percentag
read
map
annot
exon
although
provid
necessari
guidanc
rnaseq
assay
metric
earli
assess
often
use
collect
method
may
reflect
condit
observ
assess
test
impact
patient
care
publish
clinic
trial
qualiti
control
measur
test
reagent
andor
facil
longterm
monitor
patient
establish
guidelin
perform
financi
cost
econom
benefit
associ
test
educ
materi
inform
consent
requir
assess
ethic
legal
societ
implic
aris
context
test
often
test
posit
patient
diseas
clinic
outcom
often
test
neg
patient
without
diseas
clinic
outcom
proport
individu
diseas
outcom
given
preval
probabl
subject
posit
test
result
disord
outcom
diseas
outcom
neg
test
probabl
subject
truli
diseas
outcom
proport
subject
biomark
predict
outcom
diagnosi
often
test
posit
biomark
present
often
test
neg
biomark
present
repeat
reproduc
assay
within
across
laboratori
lowest
level
reliabl
detect
transcript
collect
handl
transport
sampl
impact
robust
refer
set
assess
sensit
specif
accuraci
well
test
detect
predict
clinic
diagnosi
outcom
accuraci
reliabl
test
measur
specif
biomark
within
clinic
exampl
within
oncolog
studi
transcriptom
analysi
rnaseq
come
freshfrozen
tumour
sampl
stringent
collect
term
cellular
tumour
necrosi
rna
qualiti
wherea
patholog
sampl
collect
formalin
fixat
preserv
protein
cellular
structur
rnaseq
librari
typic
prepar
total
rna
use
polyadenyl
poli
enrich
mrna
method
adequ
captur
partial
degrad
mrna
found
ffpe
sampl
given
clear
challeng
lowqual
rna
clinic
ffpe
sampl
concert
effort
focus
optim
evalu
protocol
modif
includ
rrna
deplet
ribodeplet
protocol
remov
rrna
without
poli
enrich
use
captur
sequen
cing
oligonucleotid
probe
hybrid
util
cdnacaptur
sequenc
exom
captur
rnaseq
demonstr
differenti
gene
express
analysi
ffpe
sampl
addit
differenti
express
captur
protocol
recent
appli
michigan
oncolog
sequenc
center
mioncoseq
clinic
sequenc
programm
demonstr
use
captur
librari
improv
perform
fusion
splice
junction
detect
compar
typic
poli
enrich
rnaseq
use
lowqual
rna
ffpe
sampl
analyt
tool
also
develop
evalu
effect
test
perform
comparison
studi
sever
common
softwar
tool
deseq
edger
use
analys
differenti
express
rnaseq
use
qrtpcr
microarray
result
benchmark
standard
zhang
colleagu
found
tool
differ
strength
recommend
ensemblebas
approach
combin
two
tool
reduc
falseposit
although
earli
effort
advanc
field
inde
propos
refer
standard
best
practic
substanti
largescal
effort
mainli
emerg
past
year
includ
consortium
member
span
public
regulatori
bodi
fda
nist
center
diseas
control
prevent
academ
group
industri
one
first
set
refer
standard
rnaseq
develop
synthet
rna
spikein
control
extern
rna
control
consortium
ercc
ercc
rna
spikein
control
contain
polyadenyl
transcript
preformul
two
set
full
complement
transcript
span
approxim
fold
concentr
rang
present
defin
molar
ratio
four
subgroup
stock
solut
dilut
ad
rna
sampl
thu
provid
post
hoc
measur
assay
perform
set
synthet
transcript
synthet
genefus
spikein
compos
polyadenyl
rna
transcript
correspond
known
oncogen
gene
fusion
also
avail
correspond
rnaseq
data
late
sequenc
qualiti
control
seqc
project
phase
iii
microarray
qualiti
control
maqc
consortium
associ
biomolecular
resourc
facil
abrf
independ
report
largescal
effort
defin
perform
charac
terist
rnaseq
studi
repres
remark
abl
coordin
analysi
intersampl
crossplatform
intersit
variabl
rnaseq
compar
goldstandard
method
microarray
qrtpcr
extens
use
ercc
rna
spikein
control
studi
extens
examin
assay
differ
poli
enrich
select
random
prime
plu
ribodelet
affect
reproduc
specif
fdale
seqc
studi
examin
reproduc
accuraci
rnaseq
multisit
studi
use
differ
sequenc
platform
seqc
studi
found
correl
rel
gene
express
measur
differ
rnaseq
platform
solid
life
technolog
hiseq
illumina
affymetrix
hugen
plu
microarray
taqman
qrtpcr
high
spearman
pearson
correl
coeffici
although
none
platform
provid
accur
absolut
quantif
transcript
level
base
evalu
ercc
spikein
control
titrat
valu
sensit
specif
reproduc
differenti
express
call
across
site
depend
analysi
pipelin
use
filter
appli
filter
p
valu
foldchang
express
level
improv
fals
discoveri
rate
differenti
gene
express
analysi
pipelin
show
high
reprodu
cibil
differenti
express
call
across
site
greatest
concord
highli
express
gene
consist
previou
report
seqc
studi
found
rnaseq
seen
fundament
superior
detect
novel
transcript
result
altern
splice
valid
qrtpcr
abrf
studi
examin
intraand
interlaboratori
reproduc
differ
laboratori
compar
differ
librari
prepar
method
sampl
variabl
rna
integr
sizespecif
fraction
analysi
algorithm
sequenc
platform
abrf
studi
report
overal
high
concord
normal
gene
express
measur
within
platform
spearman
correl
platform
spearman
correl
defici
crossplatform
detect
identifi
associ
readlength
analysi
approach
technolog
differ
similar
previou
report
librari
prepar
method
influenc
transcript
enrich
poli
librari
contain
exon
read
ribodeplet
librari
contain
intron
read
notabl
although
differ
observ
differenti
gene
express
result
compar
poli
enrich
ribodeplet
librari
prepar
method
well
degrad
nondegrad
rna
sampl
import
studi
goe
well
beyond
initi
report
companion
paper
help
frame
specif
area
analyt
valid
substanti
improv
particularli
relev
clinic
specimen
concord
rnaseq
microarray
report
differ
chemic
treatment
show
differenti
express
gene
correl
effect
size
treatment
given
wherea
platform
show
high
concord
qrtpcr
data
highli
express
gene
rnaseq
show
higher
concord
microarray
gene
low
express
furthermor
multipl
group
examin
role
normal
method
toward
control
bias
result
gc
content
sequenc
coverag
insert
size
seqcmaqc
abrf
consortium
paper
identifi
numer
substanti
bioinformat
challeng
must
address
rnaseq
becom
broadli
adopt
clinic
laboratori
recogn
excel
bioinformat
review
avail
elsewher
attempt
highlight
major
overarch
bioinformat
challeng
find
three
larg
theme
frequent
contribut
analysi
paralysi
develop
bioinformat
solut
rnaseq
first
lack
consensu
govern
bodi
advoc
best
practic
refer
standard
valid
rnaseq
pipelin
second
overabund
softwar
tool
option
combin
thereof
rnaseq
analysi
third
highli
complex
pipelin
consist
chain
togeth
multipl
tool
independ
develop
maintain
licens
first
probabl
relev
rnaseq
analysi
larg
grown
organ
without
extens
standard
domin
govern
bodi
comparison
standard
establish
earli
dnabas
ng
genom
project
includ
variant
call
format
vcf
binari
alignmentmap
format
bam
format
genotyp
likelihood
essenti
provid
best
practic
approach
refer
standard
ercc
spikein
control
gener
maqc
major
contributor
toward
build
reproduc
rnaseq
pipelin
pale
comparison
consensu
germlinegenom
refer
standard
human
refer
genom
consequ
lack
standard
rnaseq
provid
fertil
ground
emerg
multitud
softwar
tool
option
compet
relev
part
broad
rang
rnaseq
solut
rnaseq
pipelin
repres
laboratoryspecif
wrapper
script
chain
togeth
collect
softwar
tool
goal
report
hundr
thousand
test
result
gigabas
data
unfortun
rnaseq
pipelin
compos
sever
independ
develop
compon
continu
version
variabl
licens
challeng
clinic
test
laboratori
although
excel
agil
softwar
develop
nonregul
rapidli
chang
field
laboratori
test
use
detect
health
condit
infect
diseas
diagnost
test
perform
use
sampl
collect
patient
without
direct
physic
interact
test
patient
unit
state
vitro
diagnost
regul
us
food
drug
administr
fda
type
fertil
environ
creat
major
challeng
clinic
laboratori
exampl
wherea
genom
build
chang
everi
year
transcript
definit
often
chang
quarterli
although
fundament
challeng
bioinformat
unlik
easili
solv
framework
manag
improv
consider
ercc
seqcmaqc
abrf
consortia
provid
initi
model
refer
standard
emerg
bakeoff
best
practic
essenti
next
step
reduc
bioinformat
challeng
clinic
rnaseq
moreov
emerg
tool
allow
container
docker
provid
platform
distribut
fulli
contain
pipelin
pipelin
run
one
facil
could
reproduc
deploy
anoth
laboratori
fullpackag
pipelin
recent
emerg
express
intent
relev
clinic
applic
deploy
clinic
assay
unit
state
involv
two
path
accompani
regul
administ
us
depart
health
human
servic
hh
first
approv
clia
allow
laboratorydevelop
test
ldt
ldt
vitro
diagnost
test
develop
use
within
singl
approv
laboratori
market
toward
laboratori
clia
regul
monitor
laboratori
process
ensur
accuraci
reliabl
appropri
laboratori
test
sampl
acquisit
handl
storag
interpret
report
test
result
guidelin
approv
clia
laboratori
establish
accredit
profession
organ
colleg
american
pathologist
agenc
approv
center
medicar
medicaid
servic
cm
state
new
york
clia
regul
ldt
address
clinic
valid
clinic
util
assay
instead
provid
framework
wherebi
clinic
laboratori
valid
analyt
perform
measur
ldt
within
laboratori
facil
second
set
regul
clinic
assay
deploy
medic
devic
amend
expand
fda
oversight
market
vitro
diagnost
devic
ivd
fda
premarket
review
ivd
assur
assay
establish
analyt
clinic
valid
except
companion
diagnost
fda
typic
requir
demonstr
clinic
util
clearanc
approv
ivd
demonstr
clinic
valid
ldt
clinic
util
ldt
ivd
follow
initi
clearanc
approv
diagnost
test
clinic
util
particular
requir
broader
clinic
evalu
across
multipl
site
andor
within
clinic
trial
exampl
afirma
veracyt
microarraybas
gene
express
classifi
thyroid
nodul
assess
launch
cliaregul
ldt
subsequ
studi
report
clinic
valid
clinic
util
latter
involv
multisit
studi
demonstr
effect
afirma
test
clinic
care
recommend
result
reduct
unnecessari
surgeri
us
distinct
ng
assay
regulatori
oversight
fda
cm
emerg
area
regulatori
legisl
debat
late
fda
propos
regulatori
framework
ldt
likelihood
alter
regulatori
landscap
discuss
rnaseq
assay
move
clinic
fda
also
provid
perspect
mammoth
shift
creat
technolog
advanc
associ
ate
ng
requir
agenc
chang
current
gener
enforc
discret
fda
gener
enforc
regul
respect
ldt
activ
role
propos
premarket
review
qualiti
system
regul
requir
propos
ldt
framework
cm
clia
would
overse
laboratori
oper
test
process
fda
would
monitor
complianc
qualiti
system
regul
effect
expand
regulatori
oversight
fda
rnaseq
predic
around
fda
approv
process
first
fdaclear
ng
instrument
ng
vitro
diagnost
test
illumina
miseqdx
associ
vitro
diagnost
assay
cystic
fibrosi
illumina
miseqdx
cystic
fibrosi
cystic
fibrosi
clinic
sequenc
assay
accuraci
evalu
use
repres
subset
variant
rather
evalu
possibl
variant
reli
publicli
avail
data
support
clinic
relev
variant
although
evalu
analyt
perform
may
continu
involv
subsetbas
approach
propos
new
standard
outlin
fda
could
includ
defin
technic
metric
data
qualiti
addit
standard
comput
approach
standard
best
practic
qualiti
assur
debat
fda
oversight
larg
focus
presenc
absenc
detect
dna
variant
germlin
cystic
fibrosi
transmembran
conduct
regul
cftr
test
fda
guidanc
debat
limit
use
exampl
broad
scope
addit
regul
ngsdevelop
test
includ
rnaseq
may
provid
regulatori
uncertainti
rnaseq
imped
adopt
clinic
propos
fda
regul
around
ng
gone
without
debat
emphas
limit
enforc
capabl
regulatori
guidanc
could
unnecessarili
stifl
adopt
innov
intern
regulatori
framework
vari
across
jurisdict
evolv
practic
guidelin
regul
clinic
use
ng
exampl
european
union
eu
ivd
test
requir
ce
mark
indic
complianc
eu
ivd
direct
similar
us
eu
review
polici
chang
relat
ivd
propos
chang
harmon
ivd
market
increas
oversight
includ
use
riskbas
classif
scheme
defin
clinic
evid
requir
analyt
clinic
perform
ivd
approv
pend
regulatori
breast
cancer
subtyp
character
oestrogen
receptorneg
progesteron
receptorneg
also
known
neg
chang
us
intern
may
substanti
impact
clinic
util
rna
particularli
greater
consensu
reach
toward
refer
standard
clinic
studi
integr
dna
rna
analysi
provid
addit
evid
dysregul
mutat
gene
well
detect
gene
fusion
splice
variant
case
help
priorit
variant
therapeut
intervent
box
addit
associ
specif
genom
alter
potenti
therapeut
respons
excit
emerg
work
suggest
integr
sequenc
strategi
may
also
aid
identif
patientspecif
immunogen
neoantigen
express
tumour
recent
rnaseq
exom
sequenc
use
identifi
filter
predict
immunogen
neoantigen
express
melanoma
tumour
demonstr
associ
express
neoantigen
respons
immunecheckpoint
inhibitor
ipilimumab
integr
dna
sequenc
rnaseq
hold
promis
beyond
oncolog
exampl
transplant
field
report
emerg
util
circul
dna
monitor
transplant
reject
discuss
earlier
rnabas
measur
alreadi
use
earli
detect
reject
heart
transplant
recipi
integr
rna
dna
sequenc
improv
transplant
reject
diagnosi
import
area
current
examin
combin
genotyp
circul
dna
donor
recipi
assess
chang
express
level
may
provid
insight
degre
reject
molecular
mechan
underli
reject
could
suggest
possibl
therapeut
strategi
keep
transplant
viabl
way
integr
dna
rna
sequen
cing
could
benefit
fetal
medicin
dna
sequenc
fetu
matern
blood
combin
chang
transcript
express
level
could
provid
addit
accuraci
insight
assess
development
complic
although
challeng
exist
demonstr
util
integr
sequenc
strategi
research
studi
grow
across
broad
health
applic
point
promis
incorpor
rnaseq
clinic
medicin
unpreced
abil
simultan
detect
global
gene
transcript
level
divers
rna
speci
rnaseq
potenti
revolution
clinic
test
wide
rang
diseas
although
recent
effort
set
stage
establish
benchmark
standard
technic
analyt
best
practic
order
better
standard
rnaseq
accuraci
reproduc
precis
addit
step
toward
test
profici
valid
requir
expand
util
rnaseq
conceptu
rnaseq
shotgun
sequenc
transcriptom
lend
potenti
util
consider
hurdl
toward
translat
rna
clinic
dynam
rang
expand
approach
sampl
prepar
analysi
allow
incred
finetun
sensit
specif
reproduc
extent
flexibl
seemingli
infinit
set
option
rnaseq
spur
incred
discoveri
dynam
natur
human
diseas
also
hinder
path
clinic
particular
establish
standard
lag
recent
sever
path
forward
exist
like
mani
taken
toward
direct
use
rnaseq
clinic
applic
discoveri
phase
complet
mani
diagnost
test
becom
target
assay
sensit
enough
detect
small
number
rare
transcript
fix
natur
probe
set
microarray
qrtpcr
offer
acceler
path
clinic
test
develop
data
data
without
lure
latest
newest
analysi
method
therefor
although
rnaseq
platform
great
promis
continu
studi
need
demonstr
analyt
valid
facilit
adopt
within
clinic
laboratori
set
recent
clinic
sequenc
report
variou
group
point
valu
incorpor
rna
sequenc
rnaseq
dna
sequenc
evalu
express
mutant
allel
detect
known
novel
gene
fusion
detect
splice
variant
exampl
modi
colleagu
recent
report
result
pediatr
michigan
oncolog
sequenc
mioncoseq
programm
incorpor
clinic
exomesequenc
tumour
germlin
dna
transcriptom
sequenc
tumour
rna
manag
children
young
adult
refractori
relaps
cancer
applic
integr
sequenc
strategi
result
chang
patient
manag
case
chang
therapi
partial
complet
clinic
remiss
includ
case
potenti
action
event
mainli
gene
fusion
detect
rnaseq
absent
dna
sequenc
one
report
case
rnaseq
identifi
cryptic
fusion
involv
et
variant
detect
standard
cytogenet
fluoresc
situ
hybrid
fish
patient
precursor
b
cell
acut
lymphoblast
leukaemia
patient
maintain
molecular
remiss
follow
treatment
inhibitor
imatinib
use
rnaseq
wholegenom
sequenc
andersson
colleagu
report
fusion
detect
infant
mix
lineag
leukaemia
mll
rearrang
acut
lymphoblast
leukaemia
addit
identifi
frequent
activ
mutat
tyrosin
ra
signal
pathway
gene
low
dna
allel
frequenc
suggest
clonal
popul
howev
rnaseq
data
demonstr
express
mutant
allel
case
valu
integr
dna
rna
analysi
also
evid
clinic
research
sequenc
experi
one
exampl
wholegenom
sequenc
rnaseq
use
detect
highli
express
fusion
involv
cytotox
tlymphocyt
associ
protein
molecul
patient
advanc
syndrom
rapid
clinic
respons
note
follow
treatment
ipilimumab
monoclon
antibodi
target
integr
analysi
dna
sequenc
rnaseq
data
tripleneg
breast
cancer
sampl
also
reveal
consequ
splice
site
alter
tumour
suppressor
retinoblastoma
provid
transcript
evid
infram
exon
skip
event
suggest
result
inactiv
indic
lack
benefit
inhibitor
anoth
studi
integr
wholegenom
wholetranscriptom
analysi
cholangiocarcinoma
tumour
reveal
fibroblast
growth
factor
receptor
fusion
three
six
case
two
receiv
fgfrtarget
therapi
evid
clinic
respons
addit
case
preferenti
allelespecif
express
lossoffunct
mutat
erbb
receptor
feedback
inhibitor
neg
regul
egfr
detect
patient
went
experi
mark
diseas
regress
follow
treatment
egfr
inhibitor
togeth
select
oncolog
exampl
illustr
potenti
clinic
valu
integr
dnaand
rnabas
measur
